We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting
News

Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting

Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting
News

Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Axelar AB Presents Phase I/II Data of AXL1717 at the ASCO Annual Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Axelar AB has announced the release of a poster at The American Society of Clinical Oncology (ASCO) Annual Meeting with data from the Phase I/II trial of AXL1717 that was completed in 2011.

The poster entitled “A novel targeted oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A Phase I clinical trial.” is available on the Axelar and Karolinska Development websites (www.axelar.se and www.karolinskadevelopment.com).

Advertisement